

09,787,985 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Branellec, Didier et al

Examiner:

JC08 Rec'd PCT/PTO 23 MAR 2001
Art Unit:

Serial No.: **NOT YET ASSIGNED**

Filed: **HEREWITH**

Title: **Use of Specific Hybrid Promoters
For Controlling Tissue Expression**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231, on

3 23 2001
Date of Deposit

T. Helen Payne
Signature

EL 816576000 US

Express Mail No.

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same and does not go beyond the disclosure in the international application as filed.

Respectfully submitted,

T. Helen Payne
T. Helen Payne, Reg. No. 36,889
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-5789
Telefax (908) 231-2626

Docket No. ST98032

09/787995

JCO 1000000 23 MAR 2001

ST98032.ST25
SEQUENCE LISTING

<110> Aventis Pharma S.A.

<120> Use Of Specific Hybrid Promoters For Controlling Tissue Expression

<130> ST98032

<150> US 60/123298

<151> 1999-04-04

<150> FR/98/12000

<151> 1998-09-25

<160> 10

<170> PatentIn version 3.0

<210> 1

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(23)

<400> 1

gatggtcct acttatgctg cta

23

<210> 2

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(23)

<400> 2

cttccatcat accaaactac ata

23

<210> 3

ST98032.ST25

<211> 32
<212> DNA
<213> Artificial sequence

<220>
<221> oligonucleotide
<222> (1)..(32)

<400> 3
ctgctaaatt gctcgaggac aaattagaca aa
32

<210> 4
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<221> oligonucleotide
<222> (1)..(33)

<400> 4
ccctgacaaa gcttggctgg gctgctccac tgg
33

<210> 5
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<221> oligonucleotide
<222> (1)..(30)

<400> 5
atcgacgcgt gcccggtaca taacttacgg
30

<210> 6
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<221> oligonucleotide

ST98032.ST25

<222> (1)..(38)

<400> 6

atcgacgcgt ccgctcgagc gtcaatgggg cggagttg

38

<210> 7

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(36)

<400> 7

ccaggctgca ctcgagacta gttcccacca actcga

36

<210> 8

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(36)

<400> 8

tcgtttgaag cttggaagga gagtagcttc ggtgtc

36

<210> 9

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(30)

<400> 9

cccgttacat aacttacggt aaatggcccg

30

ST98032.ST25

<210> 10
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<221> oligonucleotide
<222> (1)..(30)

<400> 10
gggacgcgct tctacaaggc gctggccgaa
30